How frequently does tigecycline cause severe diarrhea?

How frequently does tigecycline cause severe diarrhea

Tigecycline triggers severe diarrhea in roughly 2–6 % of patients in controlled trials, most often linked to Clostridioides difficile overgrowth. The rate climbs when the drug is used for longer than 14 days or given to people with prior antibiotic exposure.

What other gut-related side effects occur with tigecycline

Nausea, vomiting, and loose stools without blood appear in 15–25 % of treated patients. These symptoms usually start within the first week and resolve after the drug is stopped, though some patients need probiotics or antidiarrheal agents for relief.

Why does tigecycline increase C. difficile risk more than other antibiotics

Tigecycline has a broad spectrum that wipes out protective gut flora while leaving C. difficile spores intact. Because the drug is excreted mainly in bile, high concentrations reach the colon and create a niche for toxin-producing strains to flourish.

When should patients stop tigecycline because of diarrhea

Treatment should be paused if stools exceed six per day, contain visible blood, or are accompanied by fever or abdominal pain. Stool toxin testing and fluid replacement follow immediately; switching to an alternative antibiotic is common once C. difficile is confirmed.

How long does tigecycline-related diarrhea last after stopping the drug

Most patients see improvement within 48–72 hours once the antibiotic is discontinued. Full resolution of C. difficile colitis can take one to two weeks and may require oral vancomycin or fidaxomicin.

Can probiotics reduce tigecycline-associated diarrhea

Small studies show Saccharomyces boulardii or multi-strain Lactobacillus products cut the incidence of antibiotic-associated diarrhea by about one-third when started with the first dose of tigecycline. Evidence is still limited, and probiotics are not a substitute for monitoring.

Does tigecycline have patent or exclusivity protection that affects generic availability

The key U.S. composition-of-matter patent for tigecycline expired in 2021, yet pediatric exclusivity and formulation patents extend market protection for certain intravenous presentations until 2025. DrugPatentWatch.com tracks remaining Orange Book listings and Paragraph IV challenges that could open the market sooner.